Northern Rockies Ecosystem Protection Act

SenesTech Announces 2022 Financial Results

Retrieved on: 
Thursday, March 16, 2023

PHOENIX, March 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"),  (www.senestech.com) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2022 financial results, with products sales increasing 77% compared to the prior year.

Key Points: 
  • PHOENIX, March 16, 2023 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"),  ( www.senestech.com ) the rodent fertility control experts and inventors of the only EPA-registered contraceptive for male and female rats, ContraPest®, today announced 2022 financial results, with products sales increasing 77% compared to the prior year.
  • We are focused on taking the foundation built in 2022 and accelerating beyond the current growth rates," added Mr. Fruendt.
  • Adjusted EBITDA loss, which is a non-GAAP measure of operating performance, for 2022 was $8.5 million compared to $7.8 million in 2021.
  • Net loss during Q4 2022 was $2.1 million, compared with a net loss of $2.5 million for Q4 2021.

SenesTech Announces Record Second Quarter 2022 Product Sales

Retrieved on: 
Thursday, August 11, 2022

PHOENIX, Aug. 11, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), (www.senestech.com) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest®, today announced record second quarter 2022 product sales, with sales increasing 73% compared to the second quarter in the prior year, and up 42% sequentially from the first quarter of 2022. The second quarter represented a new quarterly record for SenesTech, with June being the highest revenue month ever.

Key Points: 
  • PHOENIX, Aug. 11, 2022 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"), ( www.senestech.com ) the rodent fertility control experts and inventors of the only EPA registered contraceptive for male and female rats, ContraPest, today announced record second quarter 2022 product sales, with sales increasing 73% compared to the second quarter in the prior year, and up 42% sequentially from the first quarter of 2022.
  • The second quarter represented a new quarterly record for SenesTech, with June being the highest revenue month ever.
  • The Company's e-commerce platform continues to be a key driver of growth for SenesTech, representing 55% sequential revenue growth and contributing nearly 50% of overall sales during the second quarter.
  • "The second quarter represents another quarter of record quarterly sales and strong sequential growth of 42% from the most recent quarter," said Ken Siegel, SenesTech's Chief Executive Officer.

SenesTech Announces ContraPest® Deployment at California Wildlife Preserve

Retrieved on: 
Thursday, February 3, 2022

PHOENIX, Feb. 3, 2022 /PRNewswire/ --SenesTech, Inc.(NASDAQ:SNES) ( www.senestech.com ), the rodent fertility control expert announced today the deployment of ContraPestat Safari West Wildlife Preserve in northern California.

Key Points: 
  • PHOENIX, Feb. 3, 2022 /PRNewswire/ --SenesTech, Inc.(NASDAQ:SNES) ( www.senestech.com ), the rodent fertility control expert announced today the deployment of ContraPestat Safari West Wildlife Preserve in northern California.
  • It is a 400-acre private wildlife preserve and tent camp just outside Santa Rosa California.
  • As part of their integrated pest management program, they are now adding ContraPest to develop an eco-friendlier pest management program.
  • This is the latest in a growing number of ContraPest deployments within the zoo and sanctuary market around the United States.